Invivyd's chair adds CEO role ahead of readout—Chutes & Ladders
Article from Fierce Biotech about Invivyd's chair adds CEO role ahead of readout—Chutes & Ladders.
Invivyd
NASDAQ: IVVD $0.83 USD
Clinical-stage biotechnology company developing monoclonal antibodies for infectious diseases, with a focus on long-acting immunologic prophylaxis. Lead product pemivibart targets SARS-CoV-2 prevention.
Company Info
Sector:Antibodies / Infectious Disease
Headquarters:Waltham, Massachusetts, USA
Founded:2020
Website:www.invivyd.com/
Upcoming Milestones & Key Dates
2026-Q4
Clinical
Pemivibart clinical readout update
2027
Regulatory
VYD333 IND filing expected
Clinical Development Pipeline
Pemivibart (VYD222)
Target: SARS-CoV-2 spike proteinVYD333
Target: RSV F proteinVYD444
Target: Influenza hemagglutininRecent News
Leadership Team
David Hering
Chairman and Chief Executive Officer
Todd N. Tardiff
Chief Financial Officer
Jennifer Keane
Chief Medical Officer